← Leaderboards
Yubin Miao
New Mexico State University Las Cruces
$3,885,182
Attributed
$3,885,182
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $639.4K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,885,182 · 4
By mechanism
R01$3,669,265 · 2
P20$215,917 · 2
Top collaborators
No co-investigators on record.
Most similar at New Mexico State University Las Cruces
Same institution · by research overlap
- Nikos Vasilakis$7,725,066
- Glenn D Kuehn$4,188,055
- Kathryn Alyce Hanley$6,790,009
- Jeffrey B Arterburn$15,359,887
- Aravamudan S Gopalan$2,345,858
Others in their field
Top investigators on “Peptides”
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- John M Lachin · George Washington University$118,672,444
- David Heimbrook · Leidos Biomedical Research, Inc.$91,429,616
- Michael W Weiner · Northern California Institute Res &Educ$78,425,041
- Paul S. Aisen · Cognition Therapeutics, Inc.$69,846,203
- Rolf Apweiler · European Molecular Biology Laboratory$56,677,991
Research focus
PeptidesResearch DesignXenograft ProcedureMolecular TargetImageImaging DeviceFda ApprovedLung MetastaticAcidsDosimetryBraf GeneAlternative TreatmentFutureFirst-In-HumanMaximum Tolerated DoseKidneyAffinityLegal PatentClinical TrialsBiodistributionDoseCtla4 GeneCurative TreatmentsAward
Grant awards (10)
Combinations of Receptor-Targeted Alpha Radionuclide Therapy and Immune Checkpoint Inhibitors for Melanoma Treatment$557,992
R01 · FY2025 · CA · contact PI
Combinations of Receptor-Targeted Alpha Radionuclide Therapy and Immune Checkpoint Inhibitors for Melanoma Treatment$601,253
R01 · FY2024 · CA · contact PI
Combinations of Receptor-Targeted Alpha Radionuclide Therapy and Immune Checkpoint Inhibitors for Melanoma Treatment$639,351
R01 · FY2023 · CA · contact PI
Novel Receptor-Targeting Peptides for Melanoma Therapy$382,939
R01 · FY2022 · CA · contact PI
Novel Receptor-Targeting Peptides for Melanoma Therapy$390,755
R01 · FY2021 · CA · contact PI
Novel Receptor-Targeting Peptides for Melanoma Therapy$390,754
R01 · FY2020 · CA · contact PI
Novel Receptor-Targeting Peptides for Melanoma Therapy$347,733
R01 · FY2019 · CA · contact PI
Novel Receptor-Targeting Peptides for Melanoma Therapy$358,488
R01 · FY2018 · CA · contact PI
NOVEL RADIOLABELED PEPTIDES FOR NON-INVASIVE BREAST CANCER IMAGING$107,416
P20 · FY2011 · RR · contact PI
NOVEL RADIOLABELED PEPTIDES FOR NON-INVASIVE BREAST CANCER IMAGING$108,501
P20 · FY2010 · RR · contact PI